Asarina Pharma’s Board of Directors is an international team with over 100 years’ combined experience in pharmaceutical development and commercialization. The Board comprises extensive international strategic and scientific experience of executives from four countries, reflecting the global potential of Sepranolone, and Asarina Pharma’s new GAMSA family of therapies.
Paul de Potocki Chairman
MSc in Chemistry with more than 20 years’ international life science experience primarily focused on commercial operations and business & corporate development. Paul has held senior management positions with Pharmacia, Fresenius-Kabi and Biovitrum (now SOBI), and has served as CEO of stock exchange listed companies in Sweden and Norway.
SHAREHOLDING: 2,050,891 warrants which give the right to subscribe to 82,095 new shares.
Marianne Kock Board Member
Marianne is Managing Director at Ferring Pharmaceuticals Denmark, she is also SVP for Global Regulatory Affairs. She has extensive experience in R&D, clinical development, regulatory affairs and pharma development. Marianne is a Master of Science in pharmacy, from Danmarks Farmaceutiske Universitet and she holds an executive MBA. Before joining Ferring in 2002, she was Vice President at Novo Nordisk.
SHAREHOLDING: 3,000 shares. 1,025,445 warrants which give the right to subscribe to 41,017 new shares.
Miroslav Reljanovic Board Member
Dr. Miroslav Reljanovic is a medical doctor and a board-certified neurologist, and founder and Executive Chairman of Ergomed plc.
SHAREHOLDING: Ergomed Plc holds 638,332 shares
André Ulmann Board Member
André is CEO at CEMAG Consulting in Paris, was the Founder of HRA Pharma, a company he led from 1996 to 2009 as CEO, then chaired until 2016. Dr. Ulmann served as Medical Director and Head of Clinical Research for Roussel-Uclaf and Hoechst-Marion-Roussel before founding HRA Pharma, and began his career at the Necker Hospital, Paris.
SHAREHOLDING: 7,400 shares, held privately and through related parties. 1,025,445 warrants which give the right to subscribe to 41,017 new shares.
Vidar Wendel Hansen Board Member
MD, PhD from Karolinska Institutet. Vidar has more than 20 years of experience from preclinical and clinical drug development. He has worked as a medical director in both small biotechnology companies and large pharmaceutical companies, including Gilead Sciences and Novartis. Vidar has also worked as a clinical assessor at the Swedish Medical Products Agency.
SHAREHOLDING: No shares
Mathieu Simon Board Member
Dr. Mathieu Simon has held senior executive positions in many leading pharmaceutical and life science companies. He is an advisor to the European Commission Horizon 2020 Programme and a Senior Advisor at Messier Maris & Associés, an advisory M&A firm located in Paris, New York, and London, a Venture Partner at Bellevue Venture Capital in Zurich, Switzerland, an independent director at the Board of VAXIMM AG (CH) and LNC SA (FR) and a member of the Affimed supervisory board (AFMD NASDAQ). Dr. Simon was certified in internal medicine at the Faculty of Medicine, Paris Diderot University (Paris VII). He is a Graduate of the Paris Faculte de medicine, 1982.
SHAREHOLDING: No shares